$ULTRAGREEN AI SGD(UGS.SI)$ Latest news regarding Ultragreenai's US main competitor https://www.angelone.in/news/stocks/zydus-lifesciences-share-price-in-focus-us-subsidiary-agrees-to-pay-5-9-million-to-settle-litigation?utm_source=gemini&hl=en-US Zydus Lifesciences Limited's US subsidiary is set to pay $5.9 million to settle generic drug pricing case in technological

$ULTRAGREEN AI USD(ULG.SI)$ Latest news regarding Ultragreenai's US main competitor https://www.angelone.in/news/stocks/zydus-lifesciences-share-price-in-focus-us-subsidiary-agrees-to-pay-5-9-million-to-settle-litigation?utm_source=gemini&hl=en-US Zydus Lifesciences Limited's US subsidiary is set to pay $5.9 million to settle generic drug pricing case in technological

$ULTRAGREEN AI SGD(UGS.SI)$ EPS for this share before news of US competition is approx USD 0.10. Pretty obvious that they will loss market share with Zydus and Provepharm entry but numbers will likely show only in FY2027 since Healthcare Institutions go thru vigorous process to approve procurement of new est 3 to 6 months (but I would put it as 4 months on average). Hence likely their next reporting will not be affected very much (though stock price is forward looking). Bear in mind that sales of vials is approx USD 150 per vial and it is only 1 to 2% of total FGS cost hence competitors selling at USD 75 (half price) will not change the overall healthcare cost. In fact, depending on how Ultragreen contracts with their clients, their clients may

$ULTRAGREEN AI USD(ULG.SI)$ EPS for this share before news of US competition is approx USD 0.10. Pretty obvious that they will loss market share with Zydus and Provepharm entry but numbers will likely show only in FY2027 since Healthcare Institutions go thru vigorous process to approve procurement of new est 3 to 6 months (but I would put it as 4 months on average). Hence likely their next reporting will not be affected very much (though stock price is forward looking). Bear in mind that sales of vials is approx USD 150 per vial and it is only 1 to 2% of total FGS cost hence competitors selling at USD 75 (half price) will not change the overall healthcare cost. In fact, depending on how Ultragreen contracts with their clients, their clients may